Citius Oncology, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Citius Oncology, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $27 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 94% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Goodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative. Less tangible than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
+0%Cash, after subtracting all debt, equals 0% of its market value (net cash).
Lower than 67% of Healthcare companies in United States.
Tangible Assets Ratio
27%Of every $100 the company owns, $27 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 94% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 90% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Citius Oncology, Inc. made a loss over the last year. Citius Oncology, Inc. owes $0.64 for every $1 it owns. Citius Oncology, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Sep 2025.
P/E ratio
LossCitius Oncology, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.83The share price is 1.83 times Citius Oncology, Inc.'s book value per share, lower than 62% of Healthcare companies in United States.
Market cap
$74 MThe total market value of all of Citius Oncology, Inc.'s shares at today's price (share price × number of shares), smaller than 69% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$40 MWhat Citius Oncology, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.38Net worth divided by the number of shares. The share price of $0.70 is 1.8 times this, which is the P/B above.
Return on equity (ROE)
-126.6%Citius Oncology, Inc. lost 126.6% of its shareholders' money over the last year, lower than 77% of Healthcare companies in United States.
Owes vs Owns
0.64×Citius Oncology, Inc. owes $0.64 for every $1 it owns (moderate), higher than 67% of Healthcare companies in United States.
Dividend yield
NoneCitius Oncology, Inc. does not currently pay a dividend.
Profit growth
LossCitius Oncology, Inc. made a loss in each of the last two years.
Interest cover
Not coveredCitius Oncology, Inc.'s operating profit did not cover its interest costs in the year to Sep 2025.
Cash vs debt
Net cashCitius Oncology, Inc. held $0 M more cash than debt (net cash) at Sep 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Citius Oncology, Inc.: $74 M ÷ $40 M (30 Jun 2026) = 1.8.
What is Citius Oncology, Inc.'s return on equity?
Citius Oncology, Inc. lost 126.6% of its shareholders' money over the last year, lower than 77% of Healthcare companies in United States.
How much does Citius Oncology, Inc. owe compared with what it owns?
Citius Oncology, Inc. owes $0.64 for every $1 it owns (moderate), higher than 67% of Healthcare companies in United States.
Does Citius Oncology, Inc. pay a dividend?
No. Citius Oncology, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.